Seattle, WA -- (SBWIRE) -- 10/01/2019 -- Betaxolol is a special beta-receptor, primarily used to treat a medical conditions such as hypertension and glaucoma. It was first officially approved by the U.S. Food and Drug Administration (FDA) as an oral tablet in 1989. It can be used alone or in combination with other medicines to reduce the pressure within the heart or eye. Betaxolol decrease the rate of cardiac contractility selectively and actively bind and block beta-1 adrenergic receptors, which leads to a reduction in cardiac output and lower blood pressure rate. Moreover, usage of betaxolol in eyes reduces aqueous humor secretions and lowers the Intraocular Pressure (IOP), which decreases the risk of optic nerve damage and loss of vision.

Furthermore, betaxolol restricts the secretion of renin, which is released by the kidney that causes constriction of blood vessels. On the contrary, drowsiness, dizziness, lightheadedness and headaches are some of the side-effects associated with the usage of this medicine. For oral administration, betaxolol is available as 10-mg and 20-mg tablets whereas in liquid form, it comes in 2.5, 5, 10, and 15 mL of bottles of 0.25% sterile ophthalmic suspension and prescribed as one to two drops in eyes for the effective result.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1781

Rising cases of glaucoma condition around the globe are the prime factor boosting growth of the global betaxolol market. According to the Glaucoma research Foundation, glaucoma is the leading cause of irreversible blindness worldwide. Around 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be suffering from glaucoma worldwide, in 2013. Moreover, according to the American Academy of Ophthalmology, the prevalence of glaucoma is high in Africa and Latin America region. If the result of medication is negative then patients have to undergo trabeculectomy surgery.

However not every patient get the relief even after surgery, hence advanced treatments are necessary for providing relief to such patients. Therefore, reducing intra-ocular pressure is a long-term medical necessity of refractory glaucoma patients, which can deal with the use of betaxolol drug. This, in turn, is expected to offer new growth opportunities to the market. Moreover, people suffering from diabetic retinopathy are on high risk of developing glaucoma. The medical condition is associated with abnormal growth of blood vessel, which can lead to retinopathy and result in blockage of natural drainage of the eye. Therefore, rising cases of diabetes around the globe are also expected to drive the market growth.

Rising hypertension cases across the globe is also expected to boost the demand for betaxolol. According to the reports from a variety of sources, including the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), in 2015, the global prevalence of pulmonary arterial hypertension was projected to be 100,000 – 200,000, that is about 15 - 50 patients per million of the population. However, the treatment for pulmonary in arterial hypertension is limited. Whereas, Prostacyclin and prostacyclin analogs, beta-adrenergic receptor inhibitor, phosphodiesterase-5 (PDE-5) inhibitors are available to reduce symptoms, slow down the progression of the disease, and enhance the quality of life.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1781

Strict policies for approval are required to ensure the safety of drugs coupled with the patent expiry of drugs such as Betoptic S and Betoptic Liq as generic versions of these drugs are sold at 70% to 80% lower prices as compared to the branded drugs are expected to restrain the market growth.

Geographically segmentation covers North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the market and accounts for maximum share. This is owing numerous cases of diabetes and eye-related disorders among the populace in the region. According to the National Federation of the blind, 2014, around 1.3 million people were legally blind in the U.S. and over 75,000 people in the U.S. are expected to suffer from blindness or visual impairment annually. Moreover, Asia Pacific betaxolol market is expected to witness growth during the forecast period, owing to strong presence of generic key players such as Lupin Ltd. And Cipla Ltd., especially in India, as they are engaged in the production of the generics of betaxolol.

Organic and inorganic strategies by market players such as merger, collaboration, acquisition, and research and development for expansion of their business across regions is expected to boost growth of the market. For instance, in 2016, Humanwell Healthcare Group and PuraCap Pharmaceutical acquired Epic Pharma LLC for $550 million to expand both their commercial and manufacturing capabilities, as well as their presence in the U.S. and international generics market.

Market Segmentation

By Dosage Form

Tablets

Suspension

By Disease Indication

Glaucoma

Ocular Hypertension

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

The market players operating in global betaxolol market include Novartis AG, Genix Pharma (Pvt.) Ltd., East West Pharma, Hetero Healthcare Ltd. (GenX), Cadila Pharmaceuticals Ltd., Jawa Pharmaceuticals (INDIA) Pvt. Ltd., DAL Medical Services Company Ltd, Sentiss Pharma Pvt. Ltd., Humanwell Healthcare Group, and PuraCap Pharmaceutical LLC.

To view the original version on The Express Wire https://www.coherentmarketinsights.com/ongoing-insight/betaxolol-market-1781" href="">visit https://www.coherentmarketinsights.com/ongoing-insight/betaxolol-market-1781>

About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.